checkAd

    EQS-News  181  0 Kommentare CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions

    EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Annual Results/Forecast
    CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions

    09.02.2023 / 07:32 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions

    Anzeige 
    Handeln Sie Ihre Einschätzung zu CompuGroup Medical!
    Long
    27,04€
    Basispreis
    0,20
    Ask
    × 14,29
    Hebel
    Short
    30,19€
    Basispreis
    0,20
    Ask
    × 14,28
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

     

    • 10 % growth in 2022 with revenues of EUR 1,130 million
    • Organic growth of 4.1 % against strong prior year, like-for-like organic growth of 6.3 %
    • Recurring revenue increase of 10 % reflects resilience of business model
    • Strong execution in ambulatory business and excellent order intake in hospital segment 
    • Foundation laid for further growth in data solutions
    • 2023 guidance shows significant progress towards mid-term ambitions


    Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the world’s leading e-health providers, is looking back on a successful year 2022. The positive development across all segments has been the result of a strong execution on the attractive growth opportunities and investments in the healthcare sector due to ongoing digitization initiatives. Group revenues grew by 10 % to EUR 1,130 million in 2022. This development underlines the strategic path taken towards sustainable, profitable growth with investments paying off. The adjusted EBITDA margin in 2022 is still impacted by the strategic investments to accelerate digitization in healthcare, while the adjusted EBITDA grew by 4 % to a new record level. The quality of revenues, reflected by the share of recurring revenues, stood strong at 65 %. Recurring revenues grew by 10 %, underlining the robustness of CGM’s business model.

    CGM meets strategic milestones in 2022

    In 2022 CGM delivered in several strategic areas and set the course for further growth and a substantial profit increase.

    The ambulatory segment showed a strong execution on the governmental initiatives in Europe. In France, the first wave of the program Ségur has been successfully rolled out and in Germany, where large tender projects have been won, CGM is at the forefront of the market trend towards larger practices. In the US market, CGM took the first step towards the anticipated margin expansion. The rollout of eMEDIX successfully started during the second half of 2022, replacing third party providers.

    Seite 1 von 4


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Annual Results/Forecast CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions 09.02.2023 / 07:32 CET/CEST The …

    Schreibe Deinen Kommentar

    Disclaimer